Medicare
Making Medicare work for all concerned
Milliman Medicare solutions

Medicare Advantage
Learn more
Medicare Part D
Learn more
Operational consulting
Learn more
Bid development, desk review, and audit support
Milliman Medicare insight
Medicare Advantage institutional special needs plans: 2026 market landscape and future considerations
Institutional special needs plans: We offer four key takeaways on the market landscape and the future for this specialized type of Medicare Advantage offering.

State of the 2026 Medicare Advantage industry: Dual-eligible plan valuation and selected benefit offerings
We highlight changes in value-added and key-benefit trends in the Medicare Advantage market from 2025 to 2026, focusing on Dual-Eligible Special Needs Plans.
2025 Medicare FFS catheter billing anomalies and ACO implications
We detail the Medicare fee-for-service catheter billing anomalies observed during 2025 and discuss the implications for affordable care organizations.

CMS's new ACO LEAD model: What the Medicare–Medicaid integration opportunity could mean for states, plans, and providers
We explore what the Medicare-Medicaid integration opportunity could mean for states as the CMS’s new ACO LEAD model details are released.
Bleeding-related hospitalizations among direct oral anticoagulant users and nonusers in Medicare fee-for-service
Bleeding-related hospitalizations among direct oral anticoagulant users and nonusers in Medicare fee-for-service: Variation in prevalence, burden, and characteristics.

Medically frail determinations under new Medicaid requirements: Experience-based insights
We offer some experience-based insights for medically frail determinations under the new Medicaid work requirements to help states implement an accurate, compliant solution.
4 key takeaways from the third round of drugs selected for Medicare drug price negotiation
The Centers for Medicare and Medicaid Services announced the list of drugs selected for price negotiation for 2028. We broke down the implications.
6 things life sciences companies need to know about risk adjustment
What should life sciences companies know about risk adjustment for the Medicare, Medicaid, and ACA markets?
Medicare drug price negotiation: New dynamics as the tide turns to Medicare Part B
Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.
State of the 2026 Medicare Advantage industry: General enrollment plan valuation and selected benefit offerings
We highlight changes in value added and key benefit trends for general enrollment plans in the Medicare Advantage market from 2025 to 2026.
Milliman Medicare products
Milliman Commercial Reimbursement Benchmarks
Medicare Reference Pricer
Milliman MACVAT (Medicare Advantage Competitive Value Added Tool)
Health Cost Guidelines Suite
MedInsight
Medicare Repricer
Milliman ACO Builder
Medicare Suggest
Milliman Advanced Risk Adjusters
ACO Care Management Impact Model
Bundled Payment Reporting Interface
Milliman Medicare services
Milliman Medicare resources
Medicare Advantage Uniformity Flexibility benefit offerings
A review of the Uniformity Flexibility benefits offered during the contract year 2019 plan year.
Optimizing hospital partnerships
Learn why Health Alliance Plan relies on the MedInsight Hospital Evaluation and Comparison System (HECS) tool for hospital contracting.
Milliman Healthcare Analytics Blog
We dig deep into rich Milliman MedInsight data to bring you insights you won’t find anywhere else, plus updates on the state of regulatory affairs.
Identifying high-cost members
Do you know which members are likely to drive costs in the coming years? Learn how you can find out—before it’s too late to do anything about it.


